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Introduction: An international database was collected to inform the 
8th edition of the anatomic classification of lung cancer. The present 
analyses concern its primary tumor (T) component.
Methods: From 1999 to 2010, 77,156 evaluable patients, 70,967 
with non–small-cell lung cancer, were collected; and 33,115 had 
either a clinical or a pathological classification, known tumor size, 
sufficient T information, and no metastases. Survival was measured 
from date of diagnosis or surgery for clinically and pathologically 
staged tumors. Tumor-size cutpoints were evaluated by the running 
log-rank statistics. T descriptors were evaluated in a multivariate Cox 
regression analysis adjusted for age, gender, histological type, and 
geographic region.
Results: The 3-cm cutpoint significantly separates T1 from T2. From 
1 to 5 cm, each centimeter separates tumors of significantly different 
prognosis. Prognosis of tumors greater than 5 cm but less than or 
equal to 7 cm is equivalent to T3, and that of those greater than 7 cm 
to T4. Bronchial involvement less than 2 cm from carina, but without 
involving it, and total atelectasis/pneumonitis have a T2 prognosis. 
Involvement of the diaphragm has a T4 prognosis. Invasion of the 
mediastinal pleura is a descriptor seldom used.
Conclusions: Recommended changes are as follows: to subclas-
sify T1 into T1a (≤1 cm), T1b (>1 to ≤2 cm), and T1c (>2 to ≤3 cm); 
to subclassify T2 into T2a (>3 to ≤4 cm) and T2b (>4 to ≤5 cm); 
to reclassify tumors greater than 5 to less than or equal to 7 cm as 
T3; to reclassify tumors greater than 7 cm as T4; to group involve-
ment of main bronchus as T2 regardless of distance from carina; to 
group partial and total atelectasis/pneumonitis as T2; to reclassify 
diaphragm invasion as T4; and to delete mediastinal pleura invasion 
as a T descriptor.
Key Words: Lung cancer, Lung cancer staging, T component, 
T descriptors, TNM classification, Tumor size.
(J Thorac Oncol. 2015;10: 990–1003)
The 7th edition of the tumor, node, and metastasis (TNM) classification of lung cancer published in 2009 was based 
on the most thorough data-based revision ever done to date.1–3 
A retrospective international database including 81,495 evalu-
able patients collected from 1990 to 2000 by the International 
Association for the Study of Lung Cancer (IASLC) and ana-
lyzed by Cancer Research And Biostatistics (CRAB) was used 
for the revision.4 The revision consisted of changes in the T 
descriptors that emphasized the prognostic impact of tumor 
size and redefined the classification of additional tumor nod-
ules and malignant pleural effusion, the subclassification of 
M1, the validation of the classification for bronchopulmonary 
carcinoid tumors, and the rearrangement of stage grouping, 
whereas the N descriptors remained the same. Despite the 
magnitude of the database not all descriptors could be vali-
dated.5 The limitations of the retrospective database prompted 
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the IASLC to launch a call for the collection of new data.6 The 
call resulted in a new database of 77,156 evaluable patients 
diagnosed with lung cancer from 1999 to 2010.7 This new 
database is being used now to inform the 8th edition of the 
TNM classification of lung cancer due to be published in 2016.
This article presents the results of the analyses of the 
new IASLC database performed by the members of the 
Primary Tumor (T) Subcommittee of the IASLC Staging and 
Prognostic Factors Committee and the statisticians of CRAB 
concerning the T component of the TNM classification and 
its descriptors. The analyses were conducted to achieve pre-
defined objectives: to further assess the prognostic impact of 
tumor size; to assess the prognostic power of each descriptor 
defining the different T categories; and to study new condi-
tions not included in the present T descriptors, such as differ-
ences between parietal pleura and rib invasion.6
PATIENTS AND METHODS
Population
The total number of patients diagnosed with lung can-
cer between 1999 and 2010 submitted to CRAB was 94,708. 
After exclusions, 77,156 (70,967 with non–small-cell lung 
cancer [NSCLC] and 6189 with small-cell lung cancer) 
remained for analysis.7 In the NSCLC group, 33,115 patients 
met the T descriptors subcommittee’s initial analytic require-
ments of M0 NSCLC, a complete set of either clinical (c) 
TNM or pathological (p) TNM, known tumor size, and suf-
ficiently detailed T descriptors to support the assigned T cat-
egory. There was sufficient clinical T descriptor information 
for 13,012 patients, including 12,449 who were eventually 
operated, distributed as follows: 10,084 (81.0%) cN0, 907 
(7.3%) cN1, 1327 (10.7%) cN2, and 131 (1.1%) cN3. As 
for the analysis of the pathologic T, the population excluded 
those who had induction treatment and consisted of 30,018 
patients with complete pTN and M0 tumors (9915 of these 
also provided complete cTN categories; Table 1). Their dis-
tribution according to the pN component is 22,257 (74.2%) 
pN0, 3465 (11.5%) pN1, 4157 (13.9%) pN2, and 139 (0.5%) 
pN3. Asia was the geographic region that contributed most 
to the IASLC database: 10,294 (79%) patients with clinically 
staged tumors and 23,838 (79%) with pathologically staged 
ones came from Japan, South Korea, and People’s Republic of 
China (Supplementary Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A834). Adenocarcinoma was the 
most common cell type, with 64% of tumors both clinically 
and pathologically staged. Squamous cell carcinoma followed 
with 25% of clinically staged tumors and 27% of pathologi-
cally staged tumors (Supplementary Table 2, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A834). From 
the 30,018 patients with surgically resected and pathologi-
cally staged tumors, 28,150 (94%) were completely resected 
(Supplementary Table 3, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A834). To assess the completeness 
of resection, the information given by the data providers was 
considered. When the specific residual tumor (R) status was 
unknown, the case was grouped in the “any R” category.
Statistical Analysis
Survival was measured from the date of diagnosis for 
clinically staged patients and date of surgery for pathologi-
cally staged patients. Overall survival was assessed using 
the Kaplan–Meier method. Prognostic groups were assessed 
using Cox proportional hazards regression analysis.8 All sur-
vival and regression analyses were performed using SAS 
version 9.2.
Tumor-size cutpoints were evaluated using a running 
log-rank statistics produced by each hypothetical cutpoint 
in the pN0M0R0 data set graphed against tumor size.9 This 
was performed both to confirm the 7th edition T category cut-
points defined by size (T1a, b; T2a, b; and T3) and to identify 
possible additional size increments that could be useful. For 
evaluating possible new size cutpoints, the tumor size that 
coincided with the highest log-rank statistics, rounded to the 
nearest 1 cm, was chosen as the optimal cutpoint. The cho-
sen cutpoint was then tested in the context of the 7th edition 
TABLE 1.  Number of M0 Non–Small-Cell Lung Cancer Cases Passing Initial Screeninga
N0 Any N
Total T1 T2 T3 T4 Total T1 T2 T3 T4
Clinically staged
  Total 30,102 17,430 9498 2357 817 40,263 19,182 14,394 4380 2307
  Analyzed 10,230 6436 2926 719 149 13,012 7100 4239 1305 368
Clinically staged, surgically managed
  Total 29,153 17,248 9200 2178 527 36,697 18,807 13,253 3664 973
  Analyzed 10,084 6416 2873 682 113 12,449 7022 4049 1167 113
Clinically staged, nonsurgically managed
  Total 949 182 298 179 290 3566 375 1141 716 1334
  Analyzed 146 20 53 37 36 563 78 190 138 157
Pathologically staged
  Total 26,722 12,857 10,510 2780 575 36,830 14,954 15,973 4756 1147
  Analyzed 22,257 11,559 8411 2108 179 30,018 13,368 12,628 3620 402
aCriteria for T descriptor analysis: cases must have known tumor size, at least one T descriptor supporting the assigned T category, and no T descriptors suggesting a higher 
T category.
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cutpoints in a multivariate Cox regression to assess their addi-
tional prognostic significance. In addition, the cutpoints were 
assessed in the N0M0 population regardless of resection com-
pleteness, in the M0R0 population regardless of nodal status, 
and in the clinically staged N0M0 population. R software was 
used to generate the log-rank statistics.10
T descriptors were evaluated individually among the 
population of cases where the given descriptor was evaluated 
along with at least one other descriptor within the given T 
category. To isolate the effects of each descriptor individu-
ally, cases with more than one positive descriptor within a 
T category were considered separately from those with only 
one positive descriptor. Descriptors identified for potential 
reclassification, on the basis of their respective survival out-
come compared with other descriptors in the same or adja-
cent category, were then evaluated in a multivariate Cox 
regression analysis that adjusted for age, gender, histology, 
and geographic region. Specific comparisons were made 
to compare the survival of patients with a given descriptor 
against other cases within its category as defined by the 7th 
edition and against those in the proposed category. If a given 
descriptor was significantly different from others in the same 
7th edition category, and similar to those in an adjacent cat-
egory, it was considered to be evidence in support of the pro-
posed change.
Decisions on Recommendations
The objective-based preliminary analyses of the new 
IASLC database were presented at the IASLC Staging and 
Prognostic Factors Committee General Meeting that took 
place in Sydney, Australia, on October 25 and 26, 2013. Most 
committee members attended this meeting. Further analyses 
on certain descriptors, such as visceral pleural invasion, and 
univariate and multivariate analyses, were suggested. Once 
these were completed, a core group of the committee member-
ship directly involved with data analyses met with the IASLC 
statisticians at CRAB in Seattle on October 31, 2014. During 
this meeting the final recommendations were agreed upon dis-
cussion of the new results.
RESULTS
Tumor Size
The running log-rank statistics showed that the 3-cm 
cutpoint is still valid to separate T1 from T2 tumors so 
classified exclusively according to tumor size, both in the 
pathological and clinical staging settings, but also when the 
population of patients with T2 tumors includes tumors clas-
sified by othet T2 descriptors other than size (Supplementary 
Fig. 1A and B, Supplemental Digital Content 2, http://links.
lww.com/JTO/A835). These supplementary figures just 
show the 3-cm cutpoint, the best cutpoint for all sizes over 
all T categories.
When survival was analyzed by 1-cm increments in 
tumor size (≤1 cm, >1 to 2 cm, >2 to 3 cm, >3 to 4 cm, >4 to 
5 cm, >5 to 6 cm, >6 to 7 cm, and >7 cm), a progressive degra-
dation of survival was observed for each 1-cm cutpoint. This 
was found not only in the population of patients with pT1-2 
N0M0 and R0 tumors (Fig. 1A) but also in those with nodal 
involvement (Supplementary Fig. 2A, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A835) and incomplete 
resections (Supplementary Fig. 2B, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A835) and in those with 
clinically staged tumors with and without nodal involvement 
(Fig. 1B and Supplementary Fig. 2C, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A835).
Univariate and multivariate analyses to further study the 
significance of pathological tumor size controlled for age, gen-
der, cell type, and geographical region showed that survival was 
statistically significant for all tumor-size cutpoints. The 6-cm 
cutpoint did not add additional prognostic information after the 
other cutpoints were considered in a stepwise selection process 
(Table 2 and Supplementary Table 4, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A834). The same result 
was found in the univariate and multivariate analyses of clini-
cal tumor size (Supplementary Tables 5 and 6, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A834). Further 
analyses to evaluate the new 1-cm cutpoints for pT1 tumors 
showed that they distinguish between risk groups (Table 3 
and Supplementary Table 7, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A834).
A comparison of T2a less than 3 cm (T2a by descriptor 
other than size, i.e., visceral pleura invasion) versus cases of 
similar size (T1b 2–3 cm) indicated that T2a cases are appro-
priately in a higher risk category (p < 0.001; Table 3). The 
same is true for clinically staged T1 tumors (Supplementary 
Table 7, Supplemental Digital Content 1, http://links.lww.
com/JTO/A834). However, pathologically and clinically 
staged tumors greater than 5 cm but equal to or less than 7 cm 
aligned better with a T3 prognosis than with a T2b (Table 4 
and Supplementary Table 8, Supplemental Digital Content 1), 
and tumors classified as T3 by size greater than 7 cm had a 
survival similar to that of T4 tumors (Supplementary Tables 
9–12, Supplemental Digital Content 1, http://links.lww.com/
JTO/A834).
Involvement of the Main Bronchus
Involvement of the main bronchus 2 cm or more from 
the carina is well aligned as a T2 descriptor in all studied pop-
ulations with pathologically staged tumors (N0M0R0, any 
N and any R) and in the populations with clinically staged 
tumors (N0 and any N). There are no statistically significant 
differences among survival of this T2 descriptor when it is 
compared with that of other T2 descriptors (Supplementary 
Fig. 3A–E, Supplemental Digital Content 2, http://links.
lww.com/JTO/A835). On the other hand, involvement of the 
main bronchus less than 2 cm from the carina, without inva-
sion of the carina, a present T3 descriptor, has better prog-
nosis than other T3 descriptors in all studied populations 
(Supplementary Fig. 4A–E, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A835). When the prognosis of T2 
and T3 so defined by involvement of the main bronchus are 
compared, their prognosis is similar, and that of T3 main 
bronchus is better than prognosis of other T3 descriptors 
(Supplementary Fig. 5A–E, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A835). Multivariate analyses 
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showed that, in pathologically and clinically staged tumors, 
involvement of main bronchus, regardless of distance to 
carina, does not seem to increase risk after adjusting for 
tumor size. This result supports the idea that T2 main bron-
chus is similar to other T2 cases, and that T3 main bronchus 
does not show significant increased risk over T2 (Table 5 and 
Supplementary Table 13, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A834).
Atelectasis/Pneumonitis
Partial atelectasis/pneumonitis is well aligned with 
other T2 descriptors both in the pathological and in the clini-
cal settings. Five-year survival for those patients with T2 
tumors so defined by partial atelectasis/pneumonitis, only, 
and N0M0R0, for those with other T2 descriptors, and for 
those with T2 tumors by size only were 72%, 70%, and 70%, 
respectively. Similar survival rates for the three groups of 
T2 tumors were found in patients with any N and any R 
tumors and in the population of patients with cT2 N0 and 
any N tumors. Total atelectasis/pneumonitis, a T3 descriptor, 
showed better prognosis than other T3 tumors with different 
descriptors, but there were seven cases only in the pathologi-
cal setting, which precluded further analyses (Supplementary 
Table 14, Supplemental Digital Content 1, http://links.lww.
com/JTO/A834).
Visceral Pleural Invasion
Visceral pleural invasion is well positioned as a T2 
descriptor and confers a worse prognosis even after adjust-
ing for the current tumor size cutpoints (Supplementary 
Table 15, Supplemental Digital Content 1, http://links.lww.
com/JTO/A834). The extent of the visceral pleura invasion 
0 1 2 3 4 5 6
Years After Surgery
100%
A
B
80%
60%
40%
20%
0%
100%
80%
60%
40%
20%
0%
58%63 / 176pT2b: 6.1-7 cm
63%135 / 408pT2b: 5.1-6 cm
66%338 / 1058pT2a: 4.1-5 cm
73%600 / 2289pT2a: 3.1-4 cm
81%843 / 4330pT1b: 2.1-3 cm
86%803 / 5578pT1a: 1.1-2 cm
91%139 / 1401pT1a: 0.1-1 cm
EstimateDeaths / N
5-Year
by Size Only
pT1-2 N0 M0 R0 NSCLC
0 1 2 3 4 5 6
Years After Diagnosis
46%51 / 108cT2b: 6.1-7 cm
56%88 / 222cT2b: 5.1-6 cm
60%193 / 535cT2a: 4.1-5 cm
68%453 / 1526cT2a: 3.1-4 cm
76%573 / 2463cT1b: 2.1-3 cm
83%525 / 3152cT1a: 1.1-2 cm
92%69 / 790cT1a: 0.1-1 cm
EstimateDeaths / N
5-Year
by Size Only
cT1-2 N0 M0 NSCLC
FIGURE 1. A, Survival of pathologically 
staged T1–T2 N0R0 tumors according to size 
only, at 1-cm intervals. B, Survival of clinically 
staged T1–T2 N0 tumors according to size 
only, at 1-cm intervals.
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as currently defined (PL0, tumor within the subpleural lung 
parenchyma or invades superficially into the pleural con-
nective tissue beneath the elastic layer; PL1, tumor invades 
beyond the elastic layer of the visceral pleura; and PL2, 
tumor invades to the visceral pleura surface)11 appropriately 
distinguishes between risk groups, and although the progno-
sis of PL1 and PL2 is worse than that of PL0, there are also 
significant differences between PL1 and PL2, the latter hav-
ing a worse prognosis (Supplementary Table 16, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A834). 
The increased risk associated with visceral pleura invasion 
is also found in the clinical staging setting (Supplementary 
Table 17, Supplemental Digital Content 1, http://links.lww.
com/JTO/A834). Further analyses in pathologically and clini-
cally staged tumors show that pathologically staged tumor of 
greater than 3–4 cm with visceral pleura invasion has similar 
prognosis to that of those greater than 4–5 cm; and that tumors 
of greater than 4–5 cm with visceral pleura invasion have sim-
ilar prognosis to that of those greater than 5–7 cm (Table 6). 
However, these differences are not so clear in the clinically 
staged patients (Supplementary Table 18, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A834).
Diaphragm
When survival of patients with tumors involving the 
diaphragm, a present T3 descriptor, is compared with sur-
vival of patients with other T3 tumors defined by other 
descriptors, it has worse prognosis, both in the pathological 
and clinical settings. This is confirmed by the multivariate 
analyses. Patients with pT3 tumors by diaphragm involve-
ment have worse prognosis than those with pT3 tumors by 
other descriptors (p = 0.004) and even those with pT4 tumors 
(p = 0.02; Supplementary Table 19, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A834). Clinically staged 
tumors with diaphragm involvement have similar prognosis to 
those clinically classified as T4 (p = 0.09) and to those clini-
cally classified as T3 (p = 0.121). (Supplementary Table 20, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A834) The hazard ratio, however, is in the same direction as 
the pathological analyses.
TABLE 2.  Results of Univariate Analyses of Survival of Pathologically Staged T1–T3 N0M0R0 Cases According to Tumor Size 
and T2 and T3 Descriptors
Variable n/N (%)
Survival from Surgery
HR (95% CI) P value
Other histology vs. adeno 7064/21,122 (33) 2.19 (2.07, 2.32) <0.001
Squamous vs. other 5237/21,122 (25) 1.96 (1.85, 2.07) <0.001
Age ≥ 60 vs. <60 16,070/21,014 (76) 2.29 (2.11, 2.49) <0.001
Male vs. female 12,457/20,995 (59) 1.86 (1.75, 1.98) <0.001
Americas vs. Asia 1873/21,123 (9) 1.79 (1.64,1.97) <0.001
Europe/Australia vs. Asia 2361/21,123 (11) 2.61 (2.43,2.80) <0.001
Size >2 vs. ≤2 cm 12,970/21,123 (61) 1.50 (1.39,1.62) <0.001
Size >3 vs. >2–3 cm 7163/21,123 (34) 1.59 (1.47,1.70) <0.001
Size >5 vs. >3–5 cm 1925/21,123 (9) 1.45 (1.31,1.59) <0.001
Size >7 vs. >5–7 cm 606/21,123 (3) 1.45 (1.26,1.67) <0.001
Size >1 vs. ≤1 cm 19,623/21,122 (93) 2.68 (2.28, 3.14) <0.001
Size >4 vs. ≤4 cm 3669/21,122 (17) 2.43 (2.28, 2.58) <0.001
Size >6 vs. ≤6 cm 1041/21,122 (5) 2.79 (2.55, 3.06) <0.001
Multiple pT2 descriptors vs. other pT2, pT3 1817/9952 (18) 1.17 (1.07, 1.27) <0.001
pT3 vs. pT1-2 1882/21,122 (9) 2.63 (2.44, 2.83) <0.001
pT2 main bronchus >2 cm vs. all others 67/19,013 (0) 1.53 (0.98, 2.37) 0.059
pT3 main bronchus <2 cm vs. all others 24/19,013 (0) 1.82 (0.91, 3.64) 0.091
pT2 atelectasis vs. all others 161/11,869 (1) 1.98 (1.51, 2.61) <0.001
pT3 atelectasis vs. all others 8/11,869 (0) 3.06 (0.76, 12.24) 0.114
pT2 visceral pleura PL1 vs. PL0 2690/15,685 (17) 1.74 (1.60,1.89) <0.001
pT2 visceral pleura PL2 vs. PL0 813/15,685 (5) 2.23 (1.97,2.54) <0.001
pT2 3–5 cm size only vs. pT1, pT2 ≤ 3 cm 3320/21,123 (16) 1.79 (1.66,1.93) <0.001
pT2 3–5 cm plus other descriptor vs. pT1, pT2 ≤ 3 cm 1362/21,123 (6) 2.22 (2.01,2.46) <0.001
pT2 5–7 cm size only vs. pT1, pT2 ≤ 3 cm 586/21,123 (3) 2.59 (2.25,2.99) <0.001
pT2 5–7 cm plus other descriptor vs. pT1, pT2 ≤3 cm 450/21,123 (2) 2.85 (2.46,3.31) <0.001
pT3 Single descriptor vs. pT1, pT2 ≤ 3 cm 1556/21,123 (7) 3.20 (2.94,3.49) <0.001
pT3 Multiple pT3 descriptors vs. pT1, pT2 ≤ 3 cm 326/21,123 (2) 4.27 (3.66,4.99) <0.001
The p value from Wald χ2 test in Cox Regression.
HR, hazard ratio; 95% CI, 95% confidence interval; n, number with descriptor; N, number evaluated; %, percent with descriptor.
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Other T3 and T4 Descriptors
T3 descriptors parietal pericardium, mediastinal pleura, 
chest wall invasion, including Pancoast tumors and parietal 
pleural invasion, and additional tumor nodules in the same 
lobe of the primary tumor did not differ in prognosis com-
pared with other T3 tumors. In the subgroup of patients with 
tumors invading the chest wall, there were no differences in 
survival between those with parietal pleural invasion (163 
patients with tumors classified as pT3 by parietal pleura 
invasion N0M0R0, with a 56% 5-year survival rate) and those 
with more extensive chest wall involvement (405 patients with 
tumor classified as pT3 by chest wall invasion N0M0R0, with 
a 52% 5-year survival rate). Similar survivals were found for 
the pathologically staged tumors with any N and any R and 
in the clinically staged tumors with N0 and any N. Tumors 
clinically staged T3 by mediastinal pleura involvement tended 
to have better prognosis than other T3 tumors, but there were 
only 20 tumors so classified in the present database (data not 
TABLE 4.  Survival Comparisons of Pathologically Staged T2–T4 Tumors >4–5 cm, >5–7 cm, and >7 cm in Greatest Dimension
Variable n/N (%)
Survival from Surgery
HR (95% CI) P Value
Univariate Other histology vs. adeno 4357/10,028 (43) 1.61 (1.50, 1.73) <0.001
Squamous vs. other 3318/10,028 (33) 1.45 (1.35, 1.56) <0.001
Age ≥60 vs. <60 7934/9987 (79) 1.94 (1.76, 2.15) <0.001
Male vs. female 6599/9967 (66) 1.53 (1.41, 1.65) <0.001
Americas vs. Asia 762/10,028 (8) 1.24 (1.09, 1.42) 0.001
Europe/Australia vs. Asia 1439/10,028 (14) 1.90 (1.74, 2.07) <0.001
Proposed T2b 4–5 cm vs. all others 1480/10,028 (15) 1.10 (1.00, 1.21) 0.046
Proposed T3 5–7 cm vs. all others 1417/10,028 (14) 1.48 (1.35, 1.62) <0.001
Other T3 (excluding >7 cm) vs. all others 828/10,028 (8) 1.30 (1.16, 1.46) <0.001
Proposed T4 (including T3 > 7 cm) vs. all others 761/10,028 (8) 2.14 (1.92, 2.38) <0.001
Multivariate Other histology vs. adeno 4312/9940 (43) 1.28 (1.14, 1.43) <0.001
Squamous vs. other 3281/9940 (33) 0.92 (0.82, 1.03) 0.165
Age ≥60 vs. <60 7891/9940 (79) 1.95 (1.76, 2.16) <0.001
Male vs. female 6581/9940 (66) 1.46 (1.35, 1.59) <0.001
Americas vs. Asia 761/9940 (8) 1.45 (1.27, 1.66) <0.001
Europe/Australia vs. Asia 1428/9940 (14) 1.82 (1.66, 1.99) <0.001
Proposed T2b 4–5 cm vs. T2 3–4 cm 1467/9940 (15) 1.27 (1.15, 1.41) <0.001
Proposed T3 5–7 cm vs. T2 3–4 cm 1409/9940 (14) 1.59 (1.44, 1.76) <0.001
Other T3 (excluding >7 cm) vs. T2 3–4 cm 821/9940 (8) 1.62 (1.43, 1.83) <0.001
Proposed T4 (Including T3>7 cm) vs. T2 3–4 cm 757/9940 (8) 2.24 (2.00, 2.52) <0.001
Specific comparisons not shown in table: when survival of tumors greater than 5 to 7 cm is compared with that of tumors greater than 4 to 5 cm, the p value is 0.0002, indicating 
survival is significantly different for these groups. When survival of T3 tumors (excluding those >7 cm) is compared with that of tumors greater than 5 to 7 cm, the p value is 0.821, 
indicating survival is similar between these groups; p value from Wald χ2 test in Cox regression.
HR, hazard ratio; 95% CI, 95% confidence interval; n, number with descriptor; N, number evaluated; %, percent with descriptor.
TABLE 3.  Multivariate Survival Analyses of Proposed 1-cm Cutpoints in Pathologically Staged T1 Tumors
Variable n/N (%)
Survival from Surgery
HR (95% CI) P Value
Age ≥60 vs. <60 12,554/16,644 (75) 2.06 (1.87,2.28) <0.001
Americas vs. Asia 1559/16,644 (9) 2.24 (2.01,2.50) <0.001
Europe/Australia vs. Asia 1647/16,644 (10) 2.58 (2.36,2.83) <0.001
Male vs. female 9371/16,644 (56) 1.70 (1.57,1.83) <0.001
Other histology vs. adeno 4759/16,644 (29) 1.47 (1.31,1.65) <0.001
Squamous vs. other 3473/16,644 (21) 0.98 (0.87,1.10) 0.685
T1a >1–2 vs.<1 cm 5462/16,644 (33) 1.45 (1.21,1.74) <0.001
T1b >2–3 vs.<1 cm 4230/16,644 (25) 1.82 (1.52,2.18) <0.001
T2a <3 vs. <1 cm 5611/16,644 (34) 2.43 (2.04,2.90) <0.001
Each size increment distinguishes between risk groups. A comparison of T2a less than 3 cm (T2a by descriptors other than size) versus larger T1 cases (T1b > 2–3 cm, not shown 
in table) indicates that T2a cases are appropriately in a higher risk category (p < 0.001). p value from Wald χ2 test in Cox regression.
HR, hazard ratio; 95% CI, 95% confidence interval; n, number with descriptor; N, number evaluated, %=percent with descriptor.
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shown). However, at pathological staging, mediastinal pleura 
invasion seems to have worse prognosis than other pT3 tumors 
(Supplementary Table 9, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A834).
A thorough analysis of the individual T4 descriptors 
was not possible because of the small number of patients in 
each group. However, from the survival graphs that could be 
developed, involvement of the mediastinum and of the ver-
tebral body seems to be well aligned within the T4 descrip-
tors; invasion of great vessels tended to have a slightly better 
prognosis than the other T4 tumors; and invasion of the heart 
tended to have the worst (data not shown). In the selected pop-
ulation of patients with completely resected T4 tumors with 
no nodal metastases, survival is very similar to that of patients 
with completely resected T3N0 tumors.
Additional tumor nodules in a different ipsilateral lobe 
seem to have a slightly worse prognosis than other T4 descrip-
tors, but the limited number of patients precludes meaning-
ful analyses. Although having more than one additional tumor 
nodule in the same side seems to have worse prognosis than 
having only one, there are too few patients in each group to 
draw solid conclusions (data not shown).
Single versus Multiple Descriptors 
for a T Category
Multiple analyses were conducted to compare tumors 
in a given T category defined by either single or multiple 
T descriptors. Results were inconclusive, and sometimes 
they differed in the clinical and pathological settings. As an 
example, Supplementary Tables 21 and 22 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A834) show that, 
although in the pathological setting current pT2a tumors (>3 
to 5 cm) with multiple T2 descriptors might be upstaged to 
pT2b, this could not be reproduced in the clinical setting. 
Therefore, no meaningful conclusions could be drawn from 
these analyses.
Rearrangement of Descriptors
On the basis of the results described above, the follow-
ing rearrangement of descriptors was done for exploratory 
analyses: T1 tumors were subdivided into three groups at 
1 cm cutpoints (≤1 cm; >1 and ≤2 cm; and >2 and ≤3 cm); 
T2 tumors were subdivided into two subgroups (>3 and 
≤4 cm; >4 and ≤5 cm); T2 tumors greater than 5 and less than 
or equal to 7 cm were reclassified as T3; T3 tumors greater 
than 7 cm were reclassified as T4; T2 and T3 tumors so clas-
sified by endobronchial location were combined as T2; and 
invasion of the diaphragm was reclassified as T4. When 
the survival of patients with tumors classified with the new 
descriptors was studied, survival curves separated nicely with 
no crossing over or superposition. This occurred in the three 
populations with pathologically staged tumors (N0M0R0, 
any N, and any R) and in those with clinically staged tumors 
(N0M0 and any NM0). (Fig. 2A and B and Supplementary 
Fig. 6A–C, Supplemental Digital Content 2, http://links.lww.
com/JTO/A835.) In addition, all survival comparisons were 
statistically significant, including the differences between T3 
and T4, which are not significant in the current TNM classifi-
cation (Tables 7 and 8).
DISCUSSION
The analyses of tumor size in the new IASLC database 
provided solid ground not only to further subclassify tumors 
3 cm or less in size (present T1 category) and those greater 
than 3 cm (present T2 category), but also to distribute tumor 
size as a descriptor of all T categories. The survival analyses 
according to 1-cm cutpoints showed that from 1 to 5 cm every 
centimeter counts, and that larger tumors are best aligned with 
TABLE 5.  Multivariate Survival Analyses of Pathologically Staged pT2-3 Tumors Based on Their Endobronchial Location
Multivariate Results
Variable
Survival from Surgery
n/N (%) HR (95% CI) P Value
Other histology vs. adenocarcinoma 3725/8807 (42) 1.42 (1.26, 1.60) <0.001
Squamous vs. other 2868/8807 (33) 0.88 (0.78, 1.00) 0.045
Age ≥ 60 vs. <60 7031/8807 (80) 1.96 (1.76, 2.20) <0.001
Male vs. female 5807/8807 (66) 1.45 (1.33, 1.58) <0.001
Americas vs. Asia 234/8807 (3) 1.74 (1.39, 2.18) <0.001
Europe vs. Asia 1031/8807 (12) 1.98 (1.78, 2.21) <0.001
Size >2 vs. ≤ 2 cm 7640/8807 (87) 1.28 (1.09, 1.50) 0.002
Size >3 vs. 2 to ≤3 cm 6230/8807 (71) 1.09 (0.97, 1.22) 0.133
Size >5 vs. 3 to ≤5 cm 1571/8807 (18) 1.33 (1.20, 1.48) <0.001
Size >7 vs. 5 to ≤7 cm 467/8807 (5) 0.99 (0.83, 1.19) 0.953
pT2 main bronchus >2 cm from carina vs. pT2 without 
invasion
67/8807 (1) 1.08 (0.69, 1.69) 0.725
pT3 main bronchus <2 cm from carina vs. pT2 without 
invasion
24/8807 (0) 1.03 (0.51, 2.06) 0.937
pT3 other than main bronchus vs. pT2, pT3 with 
invasion of main bronchus
1304/8807 (15) 1.56 (1.39, 1.76) <0.001
p value from Wald χ2 test in Cox regression.
HR, hazard ratio; 95% CI, 95% confidence interval; n, number with descriptor; N, number evaluated; %, percent with descriptor.
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either T3 (tumor size of more than 5 to 7 cm) or T4 (tumor size 
of more than 7 cm). This finding further confirms the com-
mon intuition that the larger the tumor, the worse the progno-
sis. This study confirms that, although the 3-cm cutpoint still 
remains a landmark to separate T1 from T2 tumors, there can 
be tumors less than 2 cm in greatest dimension with signifi-
cantly different prognosis, and that the 5-cm cutpoint remains 
a useful one to separate tumors of different prognosis. The fact 
that tumors of 1 cm or less in greatest dimension are signifi-
cantly different from larger ones is important in the light of the 
results of screening programs. In screening programs, 60% to 
70% of detected lung cancers are in stage I,12,13 and 56% are 
1 cm or less in size.14 These small tumors could constitute a 
particular group worthy of further studies regarding growth 
rate, tumor density (solid, part-solid, or pure ground glass 
opacity), intensity of uptake in positron emission tomography, 
type of resection, alternative nonsurgical therapies, molecular 
characterization, and genetic signatures. The cutpoints found 
in this study work well in each studied population in the clini-
cal and pathological staging settings, represent a logical deg-
radation of survival as tumor size increases, will be relevant 
for tumor stratification in future clinical trials, will allow the 
refinement of prognosis, and can be easily applied in clinical 
practice, while keeping compatibility with the size descriptors 
of the 7th edition.
The analyses of this database could not address how to 
measure the size of part-solid adenocarcinomas with a lep-
idic component. A Subcommittee within the IASLC Staging 
TABLE 6.  Univariate and Multivariate Survival Analyses for Pathologically Staged T1, T2, and T3 Tumors Based on the Status of 
the Visceral Pleura for the Purpose of Assessing Upstaging Based on Visceral Pleura Invasion (Proposed Size Cutpoints for the 8th 
Edition)
Variable n/N (%)
Survival from Surgery
HR (95% CI) P value
Univariate Other histology vs. adeno 7020/21,007 (33) 2.20 (2.08, 2.33) <0.001
Age ≥ 60 15,970/20,899 (76) 2.28 (2.10, 2.47) <0.001
Male 12,380/20,880 (59) 1.87 (1.76, 1.99) <0.001
Americas 1871/21,007 (9) 1.55 (1.41, 1.69) <0.001
Europe/Australia 2358/21,007 (11) 2.47 (2.30, 2.65) <0.001
T1b vs. T1a 4652/20,372 (23) 0.47 (0.44, 0.51) <0.001
T1c vs. T1a 4247/20,372 (21) 0.81 (0.75, 0.87) <0.001
T2a VPI, 0.1–1 cm vs. T1a 25/20,372 (0) 0.17 (0.02, 1.20) 0.075
T2a VPI, 1–2 cm vs. T1a 692/20,372 (3) 0.81 (0.68, 0.96) 0.016
T2a VPI, 2–3 cm vs. T1a 1273/20,372 (6) 1.07 (0.96, 1.20) 0.218
T2a size only vs. T1a 2405/20,372 (12) 1.22 (1.12, 1.33) <0.001
T2a VPI, 3–4 cm vs. T1a 1147/20,372 (6) 1.58 (1.42, 1.76) <0.001
T2b size only vs. T1a 1047/20,372 (5) 1.65 (1.48, 1.84) <0.001
T2b VPI, 4–5 cm vs. T1a 433/20,372 (2) 1.93 (1.64, 2.25) <0.001
T3 vs. T1a 2245/20,372 (11) 2.36 (2.19, 2.54) <0.001
Multivariate Other histology vs. adeno 6558/20,163 (33) 1.36 (1.28, 1.45) <0.001
Age ≥ 60 15,395/20,163 (76) 2.03 (1.87, 2.22) <0.001
Male 11,862/20,163 (59) 1.64 (1.54, 1.76) <0.001
Americas 1806/20,163 (9) 2.03 (1.85, 2.24) <0.001
Europe/Australia 2174/20,163 (11) 2.25 (2.09, 2.44) <0.001
T1b vs. T1a 4603/20,163 (23) 0.91 (0.80, 1.04) 0.173
T1c vs. T1a 4213/20,163 (21) 1.28 (1.12, 1.45) <0.001
T2a VPI, 0.1–1 cm vs. T1a 25/20,163 (0) 0.26 (0.04, 1.87) 0.182
T2a VPI, 1–2 cm vs. T1a 690/20,163 (3) 1.42 (1.16, 1.73) <0.001
T2a VPI, 2–3 cm vs. T1a 1262/20,163 (6) 1.80 (1.54, 2.10) <0.001
T2a size only vs. T1a 2378/20,163 (12) 1.58 (1.38, 1.81) <0.001
T2a VPI, 3–4 cm vs. T1a 1131/20,163 (6) 2.18 (1.88, 2.53) <0.001
T2b size only vs. T1a 1035/20,163 (5) 1.92 (1.65, 2.24) <0.001
T2b VPI, 4–5 cm vs. T1a 432/20,163 (2) 2.54 (2.10, 3.07) <0.001
T3 vs. T1a 2230/20,163 (11) 2.66 (2.34, 3.03) <0.001
Specific comparisons not shown in table: T2a greater than 2 to 3 cm VPI versus T2a size only, p = 0.0661; T2a appropriate as proposed. T2a greater than 3 to 4 cm VPI versus T2a 
size only, p < 0.0001; support for upstaging to T2b. T2a greater than 3 to 4 cm VPI versus T2b size only, p = 0.0945; support for upstaging to T2b. T2b greater than 4 to 5 cm VPI versus 
T2b size only, p = 0.0036; support for upstaging to T3. T2b greater than 4 to 5 cm VPI versus T3, p = 0.5761; support for upstaging to T3. T2a 1 to 2 cm VPI versus T2a size only, 
p = 0.2399; T2a appropriate as proposed. p value from Wald χ2 test in Cox regression.
HR, hazard ratio, 95% CI, 95% confidence interval.
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and Prognostic Factors Committee was created to address 
this issue and give recommendations in a white paper that is 
being prepared at the time of this writing. In the meantime, 
the Union for International Cancer Control recommendation 
is to measure the invasive component of the tumor to define 
its T category.15 There is evidence that this measurement better 
predicts prognosis than the overall tumor size in lepidic pre-
dominant tumors.16–18
In the 7th edition of the TNM classification, involve-
ment of the main bronchus is classified as T2 if it is located 
2 cm or more from the carina and as T3 if it is less than 2 cm 
from the carina but without its invasion. This descriptor could 
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FIGURE 2. A, Survival according to 7th edition and proposed T categories for pathologically staged T1–T4 N0M0R0 tumors. B, 
Survival according to 7th edition and proposed T categories for clinically staged T1–T4 N0M0 tumors.
TABLE 7.  Survival Comparisons of Pathologically Staged Tumors According to the T Categories of the 7th Edition and to the 
Proposed T Categories for the 8th Edition
7th Edition Categories Proposed Categories
Contrast Estimate Lower Limit Upper Limit P Value Contrast Estimate Lower Limit Upper Limit P Value
T1a vs. T1b 1.3585 1.2353 1.4940 <0.0001 T1a vs. T1b 1.4899 1.2340 1.7988 <0.0001
T1b vs. T2a 1.4292 1.3162 1.5520 <0.0001 T1b vs. T1c 1.2767 1.1568 1.4090 <0.0001
T2a vs. T2b 1.2520 1.1191 1.4007 <0.0001 T1c vs. T2a 1.3647 1.2519 1.4878 <0.0001
T2b vs. T3 1.4486 1.2807 1.6384 <0.0001 T2a vs. T2b 1.2218 1.1022 1.3543 0.0001
T3 vs. T4 1.0045 0.7607 1.3264 0.9747 T2b vs. T3 1.2895 1.1553 1.4392 <0.0001
T3 vs. T4 1.2997 1.1458 1.4742 <0.0001
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not be studied reliably for the 7th edition of the TNM classifi-
cation, but data from the new IASLC database revealed that 
endobronchial tumors either less than 2 or greater than 2 cm 
from the carina have the same prognosis in the clinical and 
pathological staging. This simplifies classification as this T3 
descriptor can be merged with the T2 descriptor to form a 
single T2 descriptor in the 8th edition of the classification.
One of the consequences of endobronchial tumor 
involvement is atelectasis and pneumonitis. In the 7th edi-
tion of the TNM classification, atelectasis/pneumonitis is a 
T2 descriptor, if it does not involve the whole lung, and a T3 
descriptor, if it involves the whole lung. The present analysis 
has found that partial atelectasis/pneumonitis is well aligned 
with other T2 descriptors, but that total atelectasis/pneumoni-
tis has better survival than other T3 descriptors. Although the 
patients with total atelectasis/pneumonitis are few and it is dif-
ficult to draw data-based conclusion, it seems logical to group 
total atelectasis/pneumonitis in the T2 category as it surely 
follows the same prognostic pattern seen for endobronchial 
location. Atelectasis/pneumonitis by itself has no prognos-
tic value; it is what it represents, i.e., endobronchial growth, 
what is prognostic. While discussing this issue at the Staging 
and Prognostic Factors Committee meeting, the question of 
eliminating partial and total atelectasis/pneumonitis from the 
list of T descriptors arose. Reasons for the elimination were 
that there are few tumors classified with this descriptor and 
that the pathologists examining the resected specimen do not 
see the atelectasis because the lungs are deflated, and then, this 
descriptor cannot be used in pathological staging. It is true that 
there are few patients with completely resected tumors and no 
nodal involvement classified as T2-partial atelectasis/pneu-
monitis (95 patients) or T3-total atelectasis/pneumonitis (5 
patients). However, the numbers rise when we consider tumors 
with nodal involvement (156 patients with pT2 any N, 100 
with pT2N0 any R, and 25 with cT3 any N). For patients with 
no surgical option who will not need any further explorations, 
atelectasis/pneumonitis seen on chest radiography or computed 
tomography may be the only way to assign a T category to the 
tumor, avoiding the need of positron emission tomography or 
bronchoscopy, if these are not essential for treatment. It is also 
important to have in mind that pathological classification does 
not only derive from the pathological study performed by the 
pathologist, but from the information collected before resec-
tion. The letter of the second general rule of the TNM classifi-
cation explicitly states that pathological classification “is based 
on evidence acquired before treatment, supplemented or modi-
fied by additional evidence acquired from surgery and from 
pathological examination.”3,19,20 Therefore, a pT category based 
on the partial or total atelectasis/pneumonitis observed at clini-
cal staging can be assigned to a tumor even if the pathologist 
cannot recognize it.
Because the publication of the recommended defini-
tion of visceral pleura invasion in 2008,11 many groups have 
reviewed their experiences and published their results. Yoshida 
et al.,21 reporting on an experience of 9758 patients who had 
undergone anatomical resection and of whom 2350 had vis-
ceral pleural invasion, concluded that, for tumors 7 cm or 
less in greatest dimension, the T category should be upstaged 
to the next T category if visceral pleura invasion (VPI) was 
present. Analyzing smaller series, others have found that T2a 
tumors with VPI had worse prognosis than other T2a tumors 
so classified by tumor size only and recommended to upstage 
them to the T2b category.22–24 Shim et al.25 found that patho-
logical T2b tumors by tumor size greater than 5 cm but not 
greater than 7 cm with VPI should be upstaged to T3. Maeda 
et al.26 identified VPI as a risk factor for recurrence in com-
pletely resected stage I and II tumors, whereas Nitadori et al.27 
did not find VPI to be a risk factor for increased recurrence 
or reduced overall survival in adenocarcinomas 2 cm or less 
in greatest dimension and proposed to combine tumors of 
2 cm or less with or without VPI with those of more than 2 
but 3 cm or less without VPI into a new stage IA. The present 
analyses have shown that the presence of VPI confers worse 
prognosis even when adjusting by tumor size, and that there 
is no need to modify the present definition of visceral pleura 
invasion and its different categories (PL0, PL1, and PL2) as 
this study confirms that visceral pleura involvement is well 
positioned in the T2 category. The two categories of visceral 
pleura invasion (PL1 and PL2) are justified as there are statis-
tically significant differences between them. Detailed analyses 
of VPI in the pathological staging setting show that tumors 
greater than 3 to 4 cm with VPI have a similar prognosis to 
those greater than 4 to 5 cm; and that those greater than 4 to 
5 cm with VPI had a similar prognosis to those greater than 5 
to 7 cm. These findings could be used to upstage tumors with 
VPI to the next tumor size category, but they could not be 
replicated clearly in the clinical staging setting, indicating that 
the clinical assessment of VPI is unreliable. VPI mainly is a 
pathological descriptor. At clinical staging, it can be assumed 
by the proximity of the tumor to the lung surface and by its 
TABLE 8.  Survival Comparisons of Clinically Staged Tumors According to the T Categories of the 7th Edition and to the 
Proposed T Categories for the 8th Edition
7th Edition Categories Proposed Categories
Contrast Estimate Lower Limit Upper Limit P value Contrast Estimate Lower Limit Upper Limit P value
T1a vs. T1b 1.5534 1.3844 1.7430 <0.0001 T1a vs. T1b 1.8380 1.4274 2.3668 <0.0001
T1b vs. T2a 1.3518 1.2126 1.5070 <0.0001 T1b vs. T1c 1.4165 1.2580 1.5949 <0.0001
T2a vs. T2b 1.4465 1.2202 1.7149 <0.0001 T1c vs. T2a 1.2967 1.1543 1.4567 <0.0001
T2b vs. T3 1.2804 1.0613 1.5449 0.0098 T2a vs. T2b 1.2038 1.0309 1.4056 0.0190
T3 vs. T4 0.8851 0.6726 1.1648 0.3836 T2b vs. T3 1.3031 1.0996 1.5443 0.0022
T3 vs. T4 1.4542 1.2221 1.7305 <0.0001
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retraction, and although it could be pathologically confirmed 
(by tru-cut biopsy, by thoracoscopic biopsy, or by wedge 
resection of the tumor mass), this confirmation is not often 
done, as it is unnecessary to plan therapy. The same is true 
for the distinction of PL1 and PL2. Even if this differentia-
tion could be used to upstage tumors in case of PL2, this is 
a pathological finding that can be known at clinical staging 
only in exceptional cases. Therefore, the IASLC Staging and 
Prognostic Factors Committee members, although recogniz-
ing the prognostic value of VPI and of its different categories, 
decided not to modify its present position as a T2 descriptor, 
and not to use it to upstage tumors. However, they do recog-
nize its value in the construction of postoperative prognostic 
groups, a new project of the IASLC Staging and Prognostic 
Factors Committee. VPI is an important prognostic factor that 
has been consolidated in the analyses of the present database. 
Therefore, the recommendation to search it with elastic stains 
when it is not evident or is inconclusive with hematoxylin and 
eosin stains is valid and should be emphasized.11
Invasion of the diaphragm is a different issue. Reported 
series, usually with small number of patients, have shown that 
invasion of the diaphragm has a bad prognosis. Five-year sur-
vival for completely resected tumors ranges from 0% to 30%.28–31 
Nodal involvement, full-depth invasion, and primary repair, when 
compared with prosthetic repair, have been found to adversely 
affect prognosis.29–31 In this study, it has been confirmed that inva-
sion of the diaphragm has a worse prognosis than that assigned to 
other T3 descriptors, but that prognosis is similar to that of T4 and 
even worse for those clinically staged. Present data thus support 
the upstaging of this descriptor to the T4 category.
Mediastinal pleura invasion is seldom used as a descrip-
tor. It is difficult to determine clinically, and this may account 
for its tendency to have a better prognosis than other T3 
descriptors at clinical staging. Contrary to parietal pleura 
invasion, mediastinal pleural invasion is not associated with 
pain by itself. It can be assumed if the tumor is in contact with 
the mediastinum, but when there are more signs of mediasti-
nal invasion, the tumor has already gone beyond the medias-
tinal pleura and invaded mediastinal tissue, a T4 descriptor. 
This may explain its worse prognosis when compared with 
other pT3 descriptors. (Supplementary Table 9, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A834). At path-
ological staging, it is exceptional to find mediastinal pleura 
invasion with no more invasion into the mediastinal tis-
sue. Therefore, the IASLC Staging and Prognostic Factors 
Committee members favor the elimination of mediastinal 
pleura invasion as a T descriptor.
The analyses of the new IASLC database share some of 
the limitations of the first retrospective database used for the 7th 
edition of the TNM classification. The most important limita-
tion is that many contributing databases were not designed to 
study the TNM classification and therefore lacked the detailed 
information needed for the specific study of each descriptor. 
Although tumor size was regularly recorded in all databases, 
the other specific descriptors to define the T categories were not 
recorded, and this lack of information prevented the validation 
of many T3 and T4 descriptors. This is probably the reason why 
the analyses on the impact on prognosis of tumors classified 
by multiple descriptors, when compared with those classified 
by one descriptor, only, could not lead to solid conclusions. 
However, there was enough information to study endobronchial 
location, atelectasis/pneumonitis, visceral pleura invasion, and 
diaphragm invasion to the extent of allowing recommendations 
for changes in the 8th edition and improving the capacity to 
separate groups of tumors with significantly different progno-
sis based on their anatomical extent. When these changes are 
incorporated as new descriptors and tested for survival, the 
resulting survival graphs are better separated, and the differ-
ences in prognosis are more significant than those observed in 
the 7th edition of the TNM classification. An important result 
of this rearrangement is that survival for T3 and T4 tumors is 
now different, whereas it was not in the 7th edition. (Fig. 2A and 
B; Supplementary Fig. 6A–C, Supplemental Digital Content 
2, http://links.lww.com/JTO/A835; and Tables 7 and 8). It is 
important to note that there were insufficient patients treated by 
radiotherapy and chemotherapy alone in the database to deter-
mine the generalizability of the new recommendations across 
nonsurgical treatment modalities, as the prognostic impact of 
the T descriptors may differ depending on the therapy applied.32 
In addition, this database had a predominance of Asian patients, 
as opposed to the previous database used to inform the 7th edi-
tion that had a predominance of European cases. However, the 
multivariate analysis performed in this occasion was adjusted 
for geographical region to compensate for this geographical 
unbalance. The present database has no information on the epi-
dermal growth factor receptor mutation status of the registered 
patients with adenocarcinoma. Therefore, its prognostic impact 
could not be assessed in the present analyses.
As it was the case after the 7th edition was published, 
many specialists managing lung cancer patients used the 
changes in the classification to modify therapy. If the pro-
posed IASLC recommendations are eventually introduced in 
the 8th edition of the TNM classification, they should not be 
interpreted as basis for changing treatment. They imply a tax-
onomic refinement and not new indications of already estab-
lished treatment protocols that should ideally be derived from 
clinical trials.33,34 So, for the T component, upstaging invasion 
of the diaphragm or tumors greater than 7 cm from T3 to T4 
does not imply that these tumors should not be resected if they 
are amenable to complete resection.
In conclusion, based on the results of the analyses of the 
new IASLC database, the IASLC Staging and Prognostic Factors 
Committee recommends the following changes in the T compo-
nent for the 8th edition of the TNM classification of lung cancer:
1. The subclassification of T1 into
T1a: tumor 1 cm or less in greatest dimension,
T1b:  tumor more than 1 cm but not more than 2 cm in 
greatest dimension, and 
T1c:  tumor more than 2 cm but not more than 3 cm in 
greatest dimension;
2. The subclassification of T2 into
T2a:  tumor more than 3 cm but not more than 4 cm in 
greatest dimension and
T2b:  tumor more than 4 cm but not more than 5 cm in 
greatest dimension;
3.  The reclassification of tumors more than 5 cm but not 
more than 7 cm in greatest dimension as T3;
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4.  The reclassification of tumors more than 7 cm in greatest 
dimension as T4;
5.  The grouping of the involvement of the main bronchus 
as a T2 descriptor, regardless of distance from the carina, 
but without invasion of the carina;
6.  The grouping of partial and total atelectasis or pneumo-
nitis as a T2 descriptor;
7. The reclassification of diaphragm invasion as T4; 
8. To delete mediastinal pleura invasion as a T descriptor.
The proposed changes to the T component reduce in 
part the arbitrary nature with which some descriptors had been 
assigned in the past to a certain T category, maintain the com-
patibility with previous classifications, and improve the prog-
nostic discrimination of the different T categories. Therefore, 
they should be implemented in the new edition of the TNM 
classification of lung cancer.
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